Treatment of Attention Deficit - Hyperactivity Disorder in a Pediatric Patient with COVID-19

It is unknown that the novel Coronavirus (COVID 19), which emerged for the first time in December 2019 and spread all over the world, have affected how many children symptomatically or asymptomatically. The uncertainty of the treatment algorithm of pandemic factor and rapidly developing pandemic process created a chaotic environment in whole world. Children and adolescents have been adversely affected by this chaotic environment. Studies examining the effects of this period on the mental health of children and adolescents are scarce. It has been suggested that individuals with psychiatric disorders such as attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) adapted more difficultly and were affected more negatively than other individuals. In this study, we present a patient with ADHD and oppositional defiant disorder (ODD) who was using short-acting methylphenidate (IRIS-MPH) for treatment, had no worsening or any adverse side effects and was treated carefully for COVID 19 infection. However, further studies are required to evaluate the safety of IRIS-MPH and other psychotropic agents in patients with COVID 19.